論文

• A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
  Yamamoto J, Murata T, Tashiro Y, Higuchi T, Sugisawa N, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Hongo A, Nomura T, Saitoh W, Moriya T, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM.
  Anticancer Res. 2020 May;40(5):2509-2514. doi: 10.21873/anticanres.14221.
• Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
  Yamamoto J, Murata T, Sugisawa N, Higuchi T, Tashiro Y, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Shimoya K, Nomura T, Kurebayashi J, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM.
  Anticancer Res. 2020 May;40(5):2475-2479.
• Antibody-Conjugated Signaling Nanocavities Fabricated by Dynamic Molding for Detecting Cancers Using Small Extracellular Vesicle Markers from Tears.
  Takeuchi T, Mori K, Sunayama H, Takano E, Kitayama Y, Shimizu T, Hirose Y, Inubushi S, Sasaki R, Tanino H.
  J Am Chem Soc. 2020 Apr 8;142(14):6617-6624.
• BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study.
  Kosaka Y, Yamamoto Y, Tanino H, Nishimiya H, Yamamoto-Ibusuki M, Hirota Y, Iwase H, Nakamura S, Akashi-Tanaka S.
  Diagnostics (Basel). 2020 Feb 21;10(2). pii: E119.
• Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.
  Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino H, Yamada K, Narui K, Kimura K, Akazawa K, Kohno N; JONIE STUDY GROUP.
  Anticancer Res. 2019 Aug;39(8):4305-4314.
• [A Case of Primary Lymphoma of the Breast with Hepatic Cirrhosis].
  Saito A, Okamoto A, Konishi M, Shimada N, Fukunaga M, Sugitani Y, Tanino H, Fukushima T, Oka K.
  Gan To Kagaku Ryoho. 2019 Feb;46(2):380-382.
• Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
  Ishikawa T, Akazawa K, Hasegawa Y, Tanino H, Horiguchi J, Miura D, Hayashi M, Kohno N.
  J Surg Res. 2017 Dec;220:46-51.
• Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer
  Kosaka Y,Minatani N,Tnaka Y,Shida A,Kikuchi M,Nishimiya H,Waraya M,Katoh H,Sato T,Sengoku N,Tanino H,Yamashita K,Watanabe M
  Mol Clin Oncol. 2018 Nov;9(5):566-574.
• linical Usefulness of the Histoculture Drug Response Assay for Breast Cancer
  Hoffman RM,Tanino H
  Methods Mol Biol. 2018;1760:93-100.
• C.tuberculostearicumによる肉芽腫性乳腺炎に合併した結節性紅斑の1例
  桑原 咲, 大幡 万里恵, 福本 絢子, 小野 竜輔, 錦織 千佳子, 谷野 裕一
  皮膚の科学(1347-1813)17巻5号Page284 2018年10月